id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ajlm-1578	Hodkinson, Katherine E.; Bouwer, Nikki; Vaughan, Jenifer	South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook	2022		.htm	text/html	5471	322	50	At the time of the study, remission with reversion to chronic phase CML (based on laboratory parameters) was achieved in 22.7% (five cases) with a median remission time of 25.6 months (IQR: 12.5 months). The TKIs for the treatment of chronic phase CML at the time of this study included: the first-generation TKI, imatinib mesylate and second-generation TKI, dasatinib (on a compassionate basis) and nilotinib.	cache/ajlm-1578.htm	txt/ajlm-1578.txt